Product Description
Benzbromarone is a nonpurine xanthine oxidase inhibitor used for the treatment of gout, but never approved for use in the United States because of concerns over reports of acute liver injury and deaths with its use. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzbromarone)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | China | Dominican Republic | Egypt | Hong Kong | Malaysia | Netherlands | Pakistan | Portugal | Singapore | Slovenia | Spain | Taiwan | Thailand | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Kunshan Longdeng Ruidi Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Type 2 Diabetes|Heart Failure|Gout
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500110728 |
An Interventional study on the impact of hyperuricaemia on the prognosis of patients with heart failure with preserved ejection fraction. | N/A |
Not yet recruiting |
Heart Failure |
2028-10-31 |
|||
ChiCTR2500101365 |
ChiCTR2500101365 | N/A |
Not yet recruiting |
Gout |
2026-12-31 |
|||
ChiCTR2300077175 |
ChiCTR2300077175 | N/A |
Not yet recruiting |
Ischemic Stroke |
2026-06-30 |
2023-11-01 |
Treatments |
|
ChiCTR2400081315 |
ChiCTR2400081315 | N/A |
Not yet recruiting |
Unknown |
2025-10-31 |
2024-02-29 |
Treatments |
|
CTR20250762 |
CTR20250762 | N/A |
Completed |
Hypertension |
2025-04-22 |
2025-05-04 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244140 |
CTR20244140 | N/A |
Completed |
Hypertension |
2025-01-02 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2300068545 |
ChiCTR2300068545 | N/A |
Not yet recruiting |
Gout |
2024-12-31 |
|||
CTR20243754 |
CTR20243754 | N/A |
Completed |
Hypertension |
2024-12-23 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20243517 |
CTR20243517 | N/A |
Completed |
Unknown |
2024-10-30 |
2025-04-29 |
||
CTR20243233 |
CTR20243233 | N/A |
Completed |
Hypertension |
2024-10-09 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20242304 |
CTR20242304 | N/A |
Completed |
Hypertension |
2024-08-10 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2200057964 |
ChiCTR2200057964 | N/A |
Not yet recruiting |
Gout |
2023-02-01 |
|||
ChiCTR2200055197 |
ChiCTR2200055197 | N/A |
Recruiting |
Gout |
2023-01-04 |
|||
ChiCTR2200056024 |
ChiCTR2200056024 | N/A |
Not yet recruiting |
Gout |
2022-12-31 |
|||
ChiCTR2200061620 |
ChiCTR2200061620 | N/A |
Recruiting |
Gout |
2022-10-31 |
2023-04-02 |
Treatments |
|
ChiCTR2000035778 |
ChiCTR2000035778 | N/A |
Not yet recruiting |
Gout |
2022-09-30 |
|||
CTR20213306 |
CTR20213306 | N/A |
Completed |
Unknown |
2022-03-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2100055092 |
ChiCTR2100055092 | N/A |
Not yet recruiting |
Gout |
2022-04-01 |
|||
CTR20213305 |
CTR20213305 | N/A |
Completed |
Unknown |
2022-03-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR1900023033 |
ChiCTR1900023033 | N/A |
Recruiting |
Hypertrophy, Left Ventricular |
2021-12-31 |
|||
ChiCTR1900028684 |
ChiCTR1900028684 | N/A |
Not yet recruiting |
Unknown |
2021-12-30 |
|||
CTR20212016 |
CTR20212016 | N/A |
Completed |
Unknown |
2021-12-04 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20210876 |
CTR20210876 | N/A |
Completed |
Unknown |
2021-08-09 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2100044828 |
ChiCTR2100044828 | N/A |
Recruiting |
Gout |
2021-06-30 |
|||
2024-511111-13-01 |
2024-511111-13-01 | P4 |
Not yet recruiting |
Gout |
2025-06-30 |
2025-05-02 |
Treatments |